Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 728

1.

Design and synthesis of benzenesulfonanilides active against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus.

Namba K, Zheng X, Motoshima K, Kobayashi H, Tai A, Takahashi E, Sasaki K, Okamoto K, Kakuta H.

Bioorg Med Chem. 2008 Jun 1;16(11):6131-44. doi: 10.1016/j.bmc.2008.04.040.

PMID:
18468909
4.
5.

Synthesis and in vitro activity of dicationic bis-benzimidazoles as a new class of anti-MRSA and anti-VRE agents.

Hu L, Kully ML, Boykin DW, Abood N.

Bioorg Med Chem Lett. 2009 Mar 1;19(5):1292-5. doi: 10.1016/j.bmcl.2009.01.075.

PMID:
19208475
6.
7.
10.
11.

Seeking vancomycin resistant Staphylococcus aureus among patients with vancomycin-resistant enterococci.

Franchi D, Climo MW, Wong AH, Edmond MB, Wenzel RP.

Clin Infect Dis. 1999 Dec;29(6):1566-8.

13.

A comparison of the activities of lacticin 3147 and nisin against drug-resistant Staphylococcus aureus and Enterococcus species.

Piper C, Draper LA, Cotter PD, Ross RP, Hill C.

J Antimicrob Chemother. 2009 Sep;64(3):546-51. doi: 10.1093/jac/dkp221.

15.

Antibacterial activity of alpha-mangostin against vancomycin resistant Enterococci (VRE) and synergism with antibiotics.

Sakagami Y, Iinuma M, Piyasena KG, Dharmaratne HR.

Phytomedicine. 2005 Mar;12(3):203-8.

PMID:
15830842
17.

In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.

Cafini F, Aguilar L, González N, Giménez MJ, Torrico M, Alou L, Sevillano D, Vallejo P, Prieto J.

J Antimicrob Chemother. 2007 Jun;59(6):1185-9.

18.

Solid- and solution-phase synthesis of vancomycin and vancomycin analogues with activity against vancomycin-resistant bacteria.

Nicolaou KC, Cho SY, Hughes R, Winssinger N, Smethurst C, Labischinski H, Endermann R.

Chemistry. 2001 Sep 3;7(17):3798-823.

PMID:
11575782
19.

New anti-MRSA and anti-VRE carbapenems; synthesis and structure-activity relationships of 1beta-methyl-2-(thiazol-2-ylthio)carbapenems.

Sunagawa M, Itoh M, Kubota K, Sasaki A, Ueda Y, Angehrn P, Bourson A, Goetschi E, Hebeisen P, Then RL.

J Antibiot (Tokyo). 2002 Aug;55(8):722-57.

Items per page

Supplemental Content

Support Center